ScreenerHero

HLS HLS Therapeutics Inc.

TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · hlstherapeutics.com
3.990CAD+3.10%Mkt Cap: 87.19M $P/E: —

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and inter…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$57.06BUSD
TEVA
Teva Pharmaceutical Industries Limited Ordinary Shares
$46.10BUSDP/E 65.9
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$38.70BUSDP/E 18.3
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
ZTS
Zoetis Inc. Class A Common Stock
$28.80BUSDP/E 11.4
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated Common Stock
$11.06BUSD
RDY
Dr. Reddy's Laboratories Ltd Common Stock
$10.20BUSDP/E 29.2
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc. Class A Common Stock
$6.77BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap87.19M USD
Enterprise Value107.70M USD
Revenue (TTM)40.96M USD
Gross Profit33.08M USD
Net Income (TTM)-9.05M USD
Revenue/Share1.80 CAD
Last Price3.990 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees85
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-38.80
PEG—
EV/EBITDA8.69
EV/Revenue2.63
P/S2.13
P/B1.55
EPS (TTM)-0.37
EPS (Forward)-0.10
52W Range
0.001069% of range5.765
52W High5.765 CAD
52W Low0.0010 CAD
Profitability
Gross Margin81.83%
Oper. Margin-7.88%
EBITDA Margin30.24%
Profit Margin-22.40%
ROE-20.16%
ROA-9.04%
Growth
Revenue Growth3.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF12.48M USD
CapEx (TTM)1.24M USD
FCF Margin36.47%
FCF Yield17.13%
Net Debt20.52M USD
Net Debt/EBITDA1.66
Balance Sheet
Debt/Equity0.81
Current Ratio1.05
Quick Ratio0.76
Book Value/Sh2.50 CAD
Cash/Share0.44 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield1.57%
Payout Ratio0.00%
Ex-Div DateApr 27, 2023
Pay DateJun 15, 2023
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.515 CAD
Upside (mean)+88.3%
Target Range4.551 CAD – 12.29 CAD
4.551+88.3% to mean12.29
# Analysts4
Ownership
Shares Out.30.94M
Float19.07M
Insiders0.55%
Institutions44.60%
Short Interest
Short Ratio2.5d
Short % Out.0.66%
Shares Short204.92K
Short (prev mo.)302.31K
Technical
SMA 503.932 (+1.5%)
SMA 2004.366 (-8.6%)
Beta0.83
S&P 52W Chg14.58%
Avg Vol (30d)88.23K
Avg Vol (10d)104.82K
Technical Indicators
RSI (14)46.7
MACD0.0130
MACD Signal0.0053
MACD Hist.+0.0077
BB Upper4.237 CAD
BB Middle3.904 CAD
BB Lower3.571 CAD
BB Width17.07%
ATR (14)0.1753 CAD
Vol Ratio (20d)0.63x